Stimulant-Related Disorders
Resources for Patients and Caregivers
Stimulant use disorder captures a range of problems associated with the use of a wide variety of stimulant drugs, including meth, cocaine, and amphetamines, but not including caffeine or nicotine.
Cluster Number:
Wiki Number: 51-Stimulant-Related Disorders
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms:
Progression:
Causes:
Medications:
Therapies:
Youtube Video: Substance Related Disorders
Amazon or Library Book: The Amphetamine Debate
Click the book to link or order from Amazon.
Support Group: startyourrecovery.org; 800-662-4357
(SAMHSA-Federal Government Helpline)
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- A comparison of risk factors for relapse in opiate-related and stimulant-related substance use disorders: A cross-sectional multicenter studyby Kourosh Amini on January 3, 2023
CONCLUSION: This study reveals that despite some similarities, relapse-related situational factors in opiates and stimulants differ. Some situational factors, such as social pressure and coping with unpleasant emotions, play a more critical role in relapse to both stimulant and opiate groups.
- Rates and Patterns of Australian Emergency Department Presentations of People Who Use Stimulants: A Systematic Literature Reviewby Peter T Redona on November 21, 2022
The use of illicit stimulants continues to pose a significant challenge to different health sectors. In Australia, four particular stimulants, namely amphetamines and their derivatives, methamphetamine, ecstasy or 3,4-methylenedioxy-methamphetamine (MDMA), and cocaine cause a significant challenge to EDs as managing patients who use stimulants can be labor and resource intensive. While Australian data are available for stimulant-related ambulance attendances and hospitalizations, little is known...
- The Rising Tide of Stimulant-Related Morbidity and Mortality Warrants Evidence-Based Treatmentby Anees Bahji on September 16, 2022
No abstract
- Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysisby Kevin Y Xu on June 27, 2022
Background: Stimulant use has substantially increased among people with opioid use disorder (OUD) and is associated with worse treatment outcomes. This study's objective was to compare risk of stimulant-related emergency department (ED) and hospital admissions associated with exposure to bupropion, OUD medication (buprenorphine, naltrexone, and methadone), and selective serotonin reuptake inhibitors (SSRIs; active comparator) relative to days without active prescriptions for medication.